Venetoclax

Major

Venetoclax Relugolix Orgovyx Explained Increased relugolix exposure Details Venetoclax Colchicine Colcrys Explained Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Abrocitinib Cibinqo Explained Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Aliskiren Tekturna Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Azithromycin AzaSite Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Betrixaban Bevyxxa® Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Atorvastatin Atorvaliq Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Alogliptin Nesina Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Canagliflozin Invokana Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Venetoclax Captopril Capoten® Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Cyclosporine Injection Atopica Increased cycloSPORINE exposure, increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk o... Details Venetoclax Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure, increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk o... Details Venetoclax Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Venetoclax Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Venetoclax Digoxin Cardoxin® Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Doxorubicin Adriamycin Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Elacestrant Orserdu Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Enasidenib Idhifa Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Venetoclax Entrectinib Rozlytrek Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Everolimus Afinitor Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Felodipine Plendil® Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Fexofenadine Allegra Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Fostamatinib Tavalisse Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Ibrexafungerp Brexafemme Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Istradefylline Nourianz Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Ketoconazole Topical Extina® Foam Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and increased sensitive CYP3A4 substrate ex... Details Venetoclax Lenacapavir Injection Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Venetoclax Lenacapavir Oral Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Venetoclax Letermovir Injection Prevymis Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Venetoclax Loperamide Diamode Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Maraviroc Selzentry Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Venetoclax Meloxicam Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Venetoclax Meloxicam Injection Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Venetoclax Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Venetoclax Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Venetoclax Nafcillin Injection Unipen® Injection Reduced exposure to venetoclax and reduced venetoclax efficacy Details Venetoclax Naldemedine Symproic Increased exposure of P-gp substrate and an increased toxicities of these substrates Details